Health funders increasingly view primary care as the preferred setting for the majority of health care. To date, efforts to increase diagnostic capacity for cancer have been based on a secondary care-centred model. This can lead to longer access times, higher costs and greater risks of error and delay.
The research carried out and supported by the CanTest Collaborative aims to transform the primary care doctor’s office into a hub of diagnostic excellence. By establishing new and ongoing collaborations to identify and evaluate novel and alternative approaches to cancer detection, particularly for ‘difficult-to-diagnose’ cancers, we aim to influence policy and practice to improve cancer diagnosis and patient outcomes.
CanTest researchers will work closely with our Patient and Public Involvement (PPI) team to evaluate specific tests for cancer detection, gain international perspectives of test provision and usage, and assess patient acceptability and safety for use in primary care.
We are currently developing our research portfolio, and details of all CanTest projects will appear here. Examples of likely early studies include:
- Multi-parametric magnetic resonance imaging (mpMRI) for prostate cancer diagnosis in primary care
- The role of low dose CT in the diagnosis of lung cancer in people presenting symptoms in primary care
- Investigating early diagnosis of gynaecological cancer, including use of biomarkers +/- trans-vaginal ultrasound
- Exploring patient and practitioner preferences towards diagnostic tests for cancer and the implied risk-benefit trade-offs
- Systematic review of dermoscopy modalities
- Patient & GP experiences of tests & behavioural components (e.g. with apps and community testing)
- Patients’ and clinicians’ use and experiences of point of care tests in primary care for the diagnosis of possible cancer